Protagonist Therapeutics PTGX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -192.4%+151pp | -343.6%-353pp | 9.1%— | —— | —— | |
| Net margin | -154.9%+128pp | -282.8%-305pp | 21.9%— | —— | —— | |
| EBITDA margin | -190.4%+150pp | -340.9%-350pp | 9.6%— | —— | —— | |
| Returns | ||||||
| Return on equity | -17.1%+3.1pp | -20.2%-28.0pp | 7.8%— | —— | —— | |
| Return on assets | -15.9%+2.5pp | -18.4%-25.5pp | 7%— | —— | —— | |
| Return on invested capital | -27.6%+1.5pp | -29.1%-32.9pp | 3.8%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×-0.3× | 0.3×0.0× | 0.3×0.0× | 0.3×-0.5× | |
| Liquidity | ||||||
| Current ratio | 17.8×+5.0× | 12.7×-0.3× | 13×-3.9× | 17×-0.3× | 17.3×+4.8× | |
| Quick ratio | 17.8×+5.0× | 12.7×-0.3× | 13×-3.9× | 17×-0.3× | 17.3×+4.8× | |
| Cash ratio | 5.6×+2.8× | 2.8×+0.3× | 2.5×-2.2× | 4.7×+0.8× | 4×+1.9× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $9.30-3.8% | $9.67-4.5% | $10.12-3.8% | $10.52-3.9% | $10.94+5.5% | |
| Valuation | ||||||
| Market capitalization | $6.73B+23.2% | $5.46B+32.1% | $4.13B+24.2% | $3.33B+12.1% | $2.97B+29.0% | |
| Enterprise value | $6.54B+22.5% | $5.34B+32.6% | $4.03B+27.1% | $3.17B+11.6% | $2.84B+28.3% | |
| Price / sales | 90.8×-27.8× | 118.7×+98.9× | 19.8×+3.8× | 15.9×+1.6× | 14.3×+9.0× | |
| Price / book | 10.3×+1.4× | 8.9×+2.5× | 6.4×+1.4× | 5×+0.7× | 4.3×+0.9× | |
| EV / sales | 88.3×-27.8× | 116.1×+96.8× | 19.3×+4.1× | 15.2×+1.5× | 13.7×+8.6× | |
| Earnings yield | -1.7%+0.7pp | -2.4%-3.5pp | 1.1%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Protagonist Therapeutics's ratios come from?
- Every ratio is computed from Protagonist Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
